Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 3/20 | 0.47 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.47 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.47 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.47 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.47 |
| ▸ | ARG1 | P05089 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | BLM | P54132 | 2/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.37 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7340980 | 1.00 | CYP2D6 (0.47) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| SCHEMBL3450012 | 1.00 | CYP2D6 (0.47) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| SCHEMBL21896074 | 1.00 | CYP2D6 (0.47) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| SCHEMBL9297990 | 1.00 | CYP2D6 (0.47) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| SCHEMBL3450013 | 1.00 | CYP2D6 (0.47) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| Hydrochloric Acid SCHEMBL16287994 | 0.98 | CYP1A2 (0.46) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| Hydrochloric Acid SCHEMBL17600576 | 0.98 | CYP1A2 (0.46) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| Hydrochloric Acid SCHEMBL16288453 | 0.98 | CYP1A2 (0.46) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| SCHEMBL2339279 | 0.86 | CYP2D6 (0.44) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 | |
| SCHEMBL13675316 | 0.86 | CYP2D6 (0.44) | CYP2D6CYP1A2ALOX15CYP2C19SLC1A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 66 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4628592-A1 | PEPTIDE PRODUCTION METHOD COMPRISING STEP FOR TRANSLATING AMINO ACID HAVING OXYGEN ATOM AT SPECIFIC POSITION | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-08 | — | — | EP | disclosed |
| US-20250302912-A1 | COMPOSITION INCLUDING PEPTIDE COMPOUND AND SURFACTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-10-02 | — | — | US | disclosed |
| US-12415835-B2 | Peptide-compound cyclization method | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-16 | — | — | US | disclosed |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-09 | — | — | US | disclosed |
| EP-4609875-A2 | COMPOSITION CONTAINING PEPTIDE COMPOUND AND SURFACTANT | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-09-03 | — | — | EP | disclosed |
| EP-4603105-A1 | PHARMACEUTICAL COMPOSITION CONTAINING CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT AGAINST HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-08-20 | — | — | EP | disclosed |
| EP-4592308-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-30 | — | — | EP | disclosed |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | CHUGAI SEIYAKU KABUSHIKI KAISHA (JP) | 2025-07-29 | — | — | US | disclosed |
| EP-4166133-B1 | COMPOSITION CONTAINING PEPTIDE COMPOUND AND SURFACTANT | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-23 | — | — | EP | disclosed |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | CHUGAI PHARMACEUTICAL CO LTD (JP) | 2025-07-17 | — | — | US | disclosed |
| EP-2813512-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | Chugai Seiyaku Kabushiki Kaisha (JP) | 2014-12-17 | — | — | EP | disclosed |
| WO-2013100132-A1 | PEPTIDE-COMPOUND CYCLIZATION METHOD | 中外製薬株式会社 (JP) | 2013-07-04 | — | — | WO | disclosed |
| US-7858741-B2 | Stabilization of the collagen triple helix by O-methylation of hydroxyproline residues | WISCONSIN ALUMNI RESEARCH FOUNDATION (US) | 2010-12-28 | — | — | US | disclosed |
| US-20090264626-A1 | STABILIZATION OF THE COLLAGEN TRIPLE HELIX BY O-METHYLATION OF HYDROXYPROLINE RESIDUES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-10-22 | — | — | US | disclosed |
| EP-0618810-A4 | BRADYKININ ANTAGONIST PEPTIDES. | SCIOS NOVA INC (US) | 1994-12-07 | — | — | EP | disclosed |
| EP-0618809-A1 | BRADYKININ TYPE PEPTIDES | SCIOS NOVA INC. (US) | 1994-10-12 | — | — | EP | disclosed |
| EP-0618810-A1 | BRADYKININ ANTAGONIST PEPTIDES | SCIOS NOVA INC. (US) | 1994-10-12 | — | — | EP | disclosed |
| EP-0618809-A4 | BRADYKININ TYPE PEPTIDES. | SCIOS NOVA INC (US) | 1994-07-28 | — | — | EP | disclosed |
| WO-1992018155-A1 | BRADYKININ TYPE PEPTIDES | NOVA TECHNOLOGY LIMITED PARTNERSHIP (US) | 1992-10-29 | — | — | WO | disclosed |
| US-4316906-A | HYPOTENSIVE AGENTS | E. R. SQUIBB & SONS, INC. (US) | 1982-02-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264626-A1 | STABILIZATION OF THE COLLAGEN TRIPLE HELIX BY O-METHYLATION OF HYDROXYPROLINE RESIDUES | COL14A1, COL2A1, PLOD3 | CYP2D6 2584/4885CYP1A2 2169/4885ALOX15 3370/4885 |
| US-12410212-B2 | Cyclic compound having selective KRAS inhibitory effect on HRAS and NRAS | KRAS, HRAS, NRAS | CYP2D6 3511/4885CYP1A2 4290/4885ALOX15 4690/4885 |
| US-20250230193-A1 | CYCLIC COMPOUND HAVING SELECTIVE KRAS INHIBITORY EFFECT ON HRAS AND NRAS | KRAS, HRAS, NRAS | CYP2D6 3511/4885CYP1A2 4290/4885ALOX15 4690/4885 |
| US-12371454-B2 | Cyclic peptide compound having Kras inhibitory action | KRAS, NRAS, HRAS | CYP2D6 4576/4885CYP1A2 4845/4885ALOX15 4409/4885 |
| US-20250302912-A1 | COMPOSITION INCLUDING PEPTIDE COMPOUND AND SURFACTANT | PCTP, CETP, PLTP | CYP2D6 4748/4885CYP1A2 4802/4885ALOX15 2520/4885 |
| US-12415835-B2 | Peptide-compound cyclization method | VIP, NGLY1, GLP1R | CYP2D6 4715/4885CYP1A2 4833/4885ALOX15 3621/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.